Shares of Karyopharm Therapeutics KPTI increased 10.3% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share decreased 8.96% over the past year to ($0.73), which missed the estimate of ($0.72).
Revenue of $21,333,000 higher by 62.24% year over year, which missed the estimate of $21,450,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Nov 02, 2020
Time: 04:30 PM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2451/38092
Technicals
Company's 52-week high was at $29.61
52-week low: $11.31
Price action over last quarter: down 7.99%
Company Profile
Karyopharm Therapeutics Inc is a pharmaceutical company. The company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer. Its pipeline products of the company include Oral Selinexor, Oral Eltanexor, Oral Dual Inhibitor of PAK4 and NAMPT and Oral Verdinexor, as well as its lead product, include XPOVIO.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
